We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Pfizer health bid could give Reckitt indigestion

6 November 2017 By Carol Ryan

The maker of Gaviscon may bid for the U.S. pharma group’s consumer unit. The $15 billion or more price tag would stretch Reckitt’s balance sheet. Tough markets and the hangover from CEO Rakesh Kapoor’s last acquisition may make investors less keen to swallow another bold deal.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)